Market Overview:
The global roxithromycin market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Roxithromycin is a semi-synthetic macrolide antibiotic, which is used for the treatment of respiratory tract infections, urinary infections, and soft tissue infections. The increasing prevalence of infectious diseases and the growing demand for effective antibiotics are some of the major factors that are driving the growth of this market. Additionally, rising awareness about roxithromycin among healthcare professionals and patients is also contributing to its growth. However, stringent regulatory requirements and patent expirations are some of the major challenges faced by this market. On the basis of type, roxithromycin tablets accounted for a majority share in 2017 owing to their high demand across various applications such as respiratory tract infections (RTIs), urinary infections (UTIs), and soft tissue infections (STIs). Roxithromycin capsules are also gaining popularity due to their ease-of-use and better patient compliance as compared to tablets. On account of its high efficacy in treating RTIs caused by Mycoplasma pneumoniae strains, granules form Roxithromycin is witnessing increasing adoption in developed countries such as U.S., Canada, Germany France Italy Spain etc.
Product Definition:
Roxithromycin is a macrolide antibiotic. It is used to treat respiratory tract infections, skin and soft tissue infections, and other diseases caused by bacteria.
Roxithromycin Tablets:
Roxithromycin is a prescription antibiotic used for the treatment of bacterial infections of the respiratory tract, skin, and soft tissue. It is also used to treat rosacea and acute pharyngitis. The drug belongs to the class tetracycline antibiotics that are commonly prescribed for acne patients as well as people suffering from rosacea.
Roxithromycin Capsules:
Roxithromycin capsules are used for the treatment of respiratory infections and ophthalmic infections. It is also used as a second line of defense against bacterial infection after amoxicillin-clavulanate. Roxithromycin capsules are available in two forms, namely, 500 mg and 250 mg. The drug is marketed by GlaxoSmithKline Pharmaceuticals under the brand name “Roxithromycin” in U.S.
Application Insights:
The respiratory tract infections segment dominated the global market in 2017. This is attributed to the increasing prevalence of respiratory tract infections, such as bronchitis, cough and asthma among children and adults. According to a study published by NCBI in 2018, aroundoquarter of population aged between 0-17 years have some form of cough illness each year while half a million people die from these typesof illnesses every year globally. In addition, according to WHO estimates published in 2019, around 1 billion cases of bronchitis are reported annually worldwide with about 300 thousand hospitalizations caused by it across all age groups combined. These factors indicate that there is huge unmet medical need for Roxithromycin tablets & capsules for treating various typesof respiratory tract infections which will drive demand over the forecast period.
Regional Analysis:
North America dominated the global roxithromycin market in 2017. The presence of a large number of manufacturers coupled with high healthcare expenditure and awareness regarding this antibiotic among physicians and patients is expected to drive growth over the forecast period. In addition, increasing incidence of respiratory tract infections due to various factors such as pollution, climate change, etc., is anticipated to fuel demand for roxithromycin tablets & capsules in this region.
Asia Pacific is expected to witness fastest growth during the forecast period owing to rising prevalence of infectious diseases such as tuberculosis and dengue that are resistant against antibiotics which has led doctors prescribe drugs like roxithromycin for treatment purpose. Moreover, growing medical tourism industry along with improving healthcare infrastructure will boost demand for these products over the next eight years.
Growth Factors:
- Increasing prevalence of respiratory tract infections: Roxithromycin is a potent macrolide antibiotic that is used for the treatment of various respiratory tract infections such as bronchitis, pneumonia, and sinusitis. The increasing prevalence of respiratory tract infections is expected to drive the growth of the roxithromycin market during the forecast period.
- Rising demand for oral drugs: The growing preference for oral drugs over injectable or intravenous drugs is expected to boost the growth of the roxithromycin market during the forecast period.
- Growing awareness about antibiotics: There has been a significant increase in awareness about antibiotics in recent years, which has led to an increase in their use for various indications. This is expected to fuel the growth ofthe roxithromycin market duringthe forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Roxithromycin Market Research Report
By Type
Roxithromycin Tablets, Roxithromycin Capsules, Roxithromycin Granules
By Application
Respiratory Tract Infections, Urinary Infections, Soft Tissue Infections
By Companies
Hetero Healthcare, Finecure Pharmaceuticals, Zhejiang Zhenyuan Pharmaceutical, Johnson & Johnson, Hygeia Laboratories, Bayer AG, Allergan, Galderma SA, Valeant Pharmaceutical International, Stiefel Laboratories, Cipher, Sigma-Aldrich, Hovione
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Roxithromycin Market Report Segments:
The global Roxithromycin market is segmented on the basis of:
Types
Roxithromycin Tablets, Roxithromycin Capsules, Roxithromycin Granules
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Respiratory Tract Infections, Urinary Infections, Soft Tissue Infections
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hetero Healthcare
- Finecure Pharmaceuticals
- Zhejiang Zhenyuan Pharmaceutical
- Johnson & Johnson
- Hygeia Laboratories
- Bayer AG
- Allergan
- Galderma SA
- Valeant Pharmaceutical International
- Stiefel Laboratories
- Cipher
- Sigma-Aldrich
- Hovione
Highlights of The Roxithromycin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Roxithromycin Tablets
- Roxithromycin Capsules
- Roxithromycin Granules
- By Application:
- Respiratory Tract Infections
- Urinary Infections
- Soft Tissue Infections
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Roxithromycin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Roxithromycin is an antibiotic that is used to treat a variety of infections. It works by killing the bacteria responsible for the infection. Roxithromycin can be taken by mouth, injection, or as a cream applied to the skin.
Some of the major companies in the roxithromycin market are Hetero Healthcare, Finecure Pharmaceuticals, Zhejiang Zhenyuan Pharmaceutical, Johnson & Johnson, Hygeia Laboratories, Bayer AG, Allergan, Galderma SA, Valeant Pharmaceutical International, Stiefel Laboratories, Cipher, Sigma-Aldrich, Hovione.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Roxithromycin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Roxithromycin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Roxithromycin Market - Supply Chain
4.5. Global Roxithromycin Market Forecast
4.5.1. Roxithromycin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Roxithromycin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Roxithromycin Market Absolute $ Opportunity
5. Global Roxithromycin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Roxithromycin Market Size and Volume Forecast by Type
5.3.1. Roxithromycin Tablets
5.3.2. Roxithromycin Capsules
5.3.3. Roxithromycin Granules
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Roxithromycin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Roxithromycin Market Size and Volume Forecast by Application
6.3.1. Respiratory Tract Infections
6.3.2. Urinary Infections
6.3.3. Soft Tissue Infections
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Roxithromycin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Roxithromycin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Roxithromycin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Roxithromycin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Roxithromycin Demand Share Forecast, 2019-2026
9. North America Roxithromycin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Roxithromycin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Roxithromycin Market Size and Volume Forecast by Application
9.4.1. Respiratory Tract Infections
9.4.2. Urinary Infections
9.4.3. Soft Tissue Infections
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Roxithromycin Market Size and Volume Forecast by Type
9.7.1. Roxithromycin Tablets
9.7.2. Roxithromycin Capsules
9.7.3. Roxithromycin Granules
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Roxithromycin Demand Share Forecast, 2019-2026
10. Latin America Roxithromycin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Roxithromycin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Roxithromycin Market Size and Volume Forecast by Application
10.4.1. Respiratory Tract Infections
10.4.2. Urinary Infections
10.4.3. Soft Tissue Infections
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Roxithromycin Market Size and Volume Forecast by Type
10.7.1. Roxithromycin Tablets
10.7.2. Roxithromycin Capsules
10.7.3. Roxithromycin Granules
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Roxithromycin Demand Share Forecast, 2019-2026
11. Europe Roxithromycin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Roxithromycin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Roxithromycin Market Size and Volume Forecast by Application
11.4.1. Respiratory Tract Infections
11.4.2. Urinary Infections
11.4.3. Soft Tissue Infections
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Roxithromycin Market Size and Volume Forecast by Type
11.7.1. Roxithromycin Tablets
11.7.2. Roxithromycin Capsules
11.7.3. Roxithromycin Granules
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Roxithromycin Demand Share, 2019-2026
12. Asia Pacific Roxithromycin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Roxithromycin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Roxithromycin Market Size and Volume Forecast by Application
12.4.1. Respiratory Tract Infections
12.4.2. Urinary Infections
12.4.3. Soft Tissue Infections
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Roxithromycin Market Size and Volume Forecast by Type
12.7.1. Roxithromycin Tablets
12.7.2. Roxithromycin Capsules
12.7.3. Roxithromycin Granules
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Roxithromycin Demand Share, 2019-2026
13. Middle East & Africa Roxithromycin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Roxithromycin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Roxithromycin Market Size and Volume Forecast by Application
13.4.1. Respiratory Tract Infections
13.4.2. Urinary Infections
13.4.3. Soft Tissue Infections
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Roxithromycin Market Size and Volume Forecast by Type
13.7.1. Roxithromycin Tablets
13.7.2. Roxithromycin Capsules
13.7.3. Roxithromycin Granules
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Roxithromycin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Roxithromycin Market: Market Share Analysis
14.2. Roxithromycin Distributors and Customers
14.3. Roxithromycin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Hetero Healthcare
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Finecure Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Zhejiang Zhenyuan Pharmaceutical
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Hygeia Laboratories
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bayer AG
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Allergan
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Galderma SA
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Valeant Pharmaceutical International
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Stiefel Laboratories
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Cipher
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sigma-Aldrich
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Hovione
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
